Hemispherx Biopharma, Inc. – Product Pipeline Review – H2 2011

Hemispherx Biopharma, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Hemispherx Biopharma, Inc. - Product Pipeline Review - H2 2011” provides data on the Hemispherx Biopharma, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Hemispherx Biopharma, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Hemispherx Biopharma, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• Hemispherx Biopharma, Inc. - Brief Hemispherx Biopharma, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of Hemispherx Biopharma, Inc. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Hemispherx Biopharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the Hemispherx Biopharma, Inc.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate Hemispherx Biopharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of Hemispherx Biopharma, Inc. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the Hemispherx Biopharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with Hemispherx Biopharma, Inc..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of Hemispherx Biopharma, Inc. and identify potential opportunities in those areas.

Contents

Hemispherx Biopharma, Inc. Snapshot
Hemispherx Biopharma, Inc. Overview
Key Information
Key Facts
Hemispherx Biopharma, Inc. – Research and Development Overview
Key Therapeutic Areas
Hemispherx Biopharma, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Hemispherx Biopharma, Inc. – Pipeline Products Glance
Hemispherx Biopharma, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Hemispherx Biopharma, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Hemispherx Biopharma, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Hemispherx Biopharma, Inc. – Drug Profiles
Alferon N Injection
Product Description
Mechanism of Action
R&D Progress
Ampligen
Product Description
Mechanism of Action
R&D Progress
Hemispherx Biopharma, Inc. – Pipeline Analysis
Hemispherx Biopharma, Inc. – Pipeline Products by Therapeutic Class
Hemispherx Biopharma, Inc. - Pipeline Products By Target
Hemispherx Biopharma, Inc. – Pipeline Products by Route of Administration
Hemispherx Biopharma, Inc. – Pipeline Products by Molecule Type
Hemispherx Biopharma, Inc. – Recent Pipeline Updates
Hemispherx Biopharma, Inc. - Dormant Projects
Hemispherx Biopharma, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Oragen
Hemispherx Biopharma, Inc. – Company Statement
Hemispherx Biopharma, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 31, 2007: Hemispherx Presents Primate Results Of Alferon-LDO In Potential Avian Influenza
Nov 29, 2010: Hemispherx Requests FDA For Extension Of Time For Ampligen NDA Submission
Jan 28, 2010: Stanford University Publishes New Data On Immuno-Potential Of Hemispherx’s Ampligen
Aug 27, 2007: Hemispherx Announces Increase In Revenues from Alferon N Injection HPV Indication Under Armada Specialty Pharmacy Agreement
May 26, 2009: Hemispherx Biopharma Announces Possible Brief Delay In Fda Action On Ampligen New Drug Application
Apr 23, 2007: Hemispherx And Armada Health Care Enter Agreement To Launch Alferon N Injection Via Specialty Pharmacy Network
Nov 22, 2010: Hemispherx Announces Publication Of New Data On Ampligen’s Activity In Chronic Fatigue Syndrome In Journal Of Applied Research
Nov 22, 2004: Hemispherx Biopharma Initiates Alferon LDO Clinical Program In Collaboration With Princess Margaret Hospital In Hong Kong
Jun 21, 2011: Hemispherx Biopharma’s Ampligen Tested In Combination With Experimental Vaccine For Ovarian Cancer Treatment
Jul 20, 2011: Hemispherx Receives FDA Authorization To Initiate New Clinical Trial Of Intranasal Ampligen
Jul 19, 2011: Hemispherx Biopharma Receives US Patent For Use Of Ampligen As Influenza Virus Vaccine
Jul 19, 2010: Hemispherx Receives Indian Approval For Initiation Of Clinical Study With Alferon N Injection In Hospitalized Flu Patients
Aug 18, 2003: Hemispherx Biopharma Enters Into Sales And Marketing Agreement With Engitech For Alferon N
Mar 18, 2004: Hemispherx Biopharma Completes Acquisition For Worldwide Rights To Alferon N
Mar 18, 2004: Hemispherx Biopharma Completes Acquisition For Worldwide Rights To Alferon N
Aug 17, 2011: Hemispherx Biopharma Submits Regulatory Approval For Alferon In Argentina
May 17, 2010: Hemispherx Prepares Application To Initiate Phase II Clinical Trials In China With Ampligen
May 16, 2005: Hemispherx Biopharma Initiates Clinical Trials Of Alferon LDO For Avian Flu And Other Viral Diseases
Feb 16, 2006: Hemispherx Biopharma Unveils Rresults Of Investigational Immunotherapeutics Alferon In Patients With Avian flu
Dec 14, 2010: Hemispherx Receives FDA Extension For Pending NDA Of Chronic Fatigue Syndrome Treatment
Jun 14, 2004: Hemispherx Biopharma Launches Multiple Sclerosis Salvage Program With Natural Interferons
Jan 14, 2010: Hemispherx Biopharma Addresses Ampligen CFS Preclinical Issues
Jul 12, 2010: Hemispherx Reports Successful Culmination Of Three Year Joint Research Program At Japanese NIID
May 12, 2011: Hemispherx Biopharma’s Ampligen Cited At Barcelona Vaccine & Active Immunotherapeutics Forum 2011
Apr 11, 2005: Hemispherx Biopharma’S Investigational Drug Increases Physical Performance In New Chronic Fatigue Syndrome (Cfs) Clinical Study
Jan 09, 2008: Hemispherx Biopharma Addresses FDA Questions On Ampligen NDA
Sep 08, 2010: Hemispherx To Present New Retrovirus Data At First International Workshop On XMRV And Chronic Fatigue Syndrome
Feb 08, 2010: Hemispherx Biopharma Announces Independent University Researchers Report Study Results Of Ampligen Against SARS Virus
Apr 07, 2008: Hemispherx Biopharma Accelerates Ampligen As A Potential Adjuvant For Both Avian Influenza And Hiv Vaccines
Oct 06, 2008: Hemispherx Engages The Sage Group As Its Corporate Partnership Advisor For Ampligen To Treat Chronic Fatigue Syndrome
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
Apr 04, 2011: Hemispherx Presents Encouraging Animal Model Data Of Tumor Vaccine Adjuvant - Ampligen At AACR
Jan 04, 2011: Hemispherx Receives FDA Clearance For Alferon LDO Phase II Study In Influenza
Sep 02, 2009: Hemispherx Biopharma Presents Data On New Comparative Analysis Of Alferon LDO In Pandemic Influenza
Jun 02, 2008: Hemispherx Biopharma Completes Enrollment In Phase Ii Study Of Ampligen As Seasonal Flu Vaccine Enhancer
Mar 02, 2004: Hemispherx Biopharma Initiates Phase II Study Of Alferon LDO In HIV Patients
Feb 02, 2010: Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That The FDA Seattle District Accepts Ampligen Manufacturing Response
Jun 01, 2004: Hemispherx Biopharma Receives Approval For West Nile Virus Protocol With Alferon N Treatment
Financial Deals Landscape
Hemispherx Biopharma, Inc., Deals Summary
Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Hemispherx Biopharma Acquires Rights For DOGS From Vanderbilt University
Hemispherx Biopharma Acquires Royalty Interest From Stem Cell Innovations
Partnerships
Hemispherx Biopharma Enters Into Co-Development Agreement With Max Neeman
Hemispherx Enters Into Agreement With Armada Health Care
Hemispherx Biopharma Enters Into Research Agreement with Defence R&D Canada
Hemispherx Biopharma Signs Research Agreement With National Institute of Infectious Diseases
Hemispherx Biopharma Forms Collaboration With Vanderbilt University
Licensing Agreements
Hemispherx Biopharma Enters Into Licensing And Marketing Agreement With GP Pharm For Alferon
Hemispherx Biopharma Amends Its Licensing And Marketing Agreement With GP Pharm
Hemispherx Biopharma Enters Into Licensing And Marketing Agreement With GP Pharm
Hemispherx Biopharma Enters Into A Licensing Agreement With BIKEN
Equity Offering
Hemispherx Biopharma Raises $0.29 Million Through Private Placement
Hemispherx Biopharma Raises $3 Million From Exercise Of Series II Warrants
Hemispherx Biopharma Raises $2 Million From Exercise Of Warrants
Hemispherx Biopharma Completes Private Placement Of Common Stock For $16 Million
Hemispherx Biopharma Completes Private Placement Of $15 Million
Hemispherx Biopharma Completes Private Placement Of $7 Million
Hemispherx Biopharma Raises $2.2 Million Through Exercise Of Warrants
Debt Offering
Hemispherx Biopharma Completes Private Placement Of 6% Debentures For $4 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Hemispherx Biopharma, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Hemispherx Biopharma, Inc. – Pipeline by Stage of Development, H2 2011
Hemispherx Biopharma, Inc. – Monotherapy Products in Pipeline, H2 2011
Hemispherx Biopharma, Inc. – Phase III, H2 2011
Hemispherx Biopharma, Inc. - Phase II, H2 2011
Hemispherx Biopharma, Inc. - Pipeline By Therapeutic Class, H2 2011
Hemispherx Biopharma, Inc. - Pipeline By Target, H2 2011
Hemispherx Biopharma, Inc. – Pipeline By Route of Administration, H2 2011
Hemispherx Biopharma, Inc. – Pipeline By Molecule Type, H2 2011
Hemispherx Biopharma, Inc. – Recent Pipeline Updates, H2 2011
Hemispherx Biopharma, Inc. - Dormant Developmental Projects, 2010
Hemispherx Biopharma, Inc. - Discontinued Pipeline Products, 2010
Hemispherx Biopharma, Inc., Other Locations
Hemispherx Biopharma, Inc., Subsidiaries
Hemispherx Biopharma, Inc., Deals Summary
Hemispherx Biopharma Acquires Rights For DOGS From Vanderbilt University
Hemispherx Biopharma Acquires Royalty Interest From Stem Cell Innovations
Hemispherx Biopharma Enters Into Co-Development Agreement With Max Neeman
Hemispherx Enters Into Agreement With Armada Health Care
Hemispherx Biopharma Enters Into Research Agreement with Defence R&D Canada
Hemispherx Biopharma Signs Research Agreement With National Institute of Infectious Diseases
Hemispherx Biopharma Forms Collaboration With Vanderbilt University
Hemispherx Biopharma Enters Into Licensing And Marketing Agreement With GP Pharm For Alferon
Hemispherx Biopharma Amends Its Licensing And Marketing Agreement With GP Pharm
Hemispherx Biopharma Enters Into Licensing And Marketing Agreement With GP Pharm
Hemispherx Biopharma Enters Into A Licensing Agreement With BIKEN
Hemispherx Biopharma Raises $0.29 Million Through Private Placement
Hemispherx Biopharma Raises $3 Million From Exercise Of Series II Warrants
Hemispherx Biopharma Raises $2 Million From Exercise Of Warrants
Hemispherx Biopharma Completes Private Placement Of Common Stock For $16 Million
Hemispherx Biopharma Completes Private Placement Of $15 Million
Hemispherx Biopharma Completes Private Placement Of $7 Million
Hemispherx Biopharma Raises $2.2 Million Through Exercise Of Warrants
Hemispherx Biopharma Completes Private Placement Of 6% Debentures For $4 Million

LIST OF FIGURES

Hemispherx Biopharma, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Hemispherx Biopharma, Inc. – Pipeline by Stage of Development, H2 2011
Hemispherx Biopharma, Inc. – Monotherapy Products in Pipeline, H2 2011
Hemispherx Biopharma, Inc. – Pipeline By Therapeutic Class, H2 2011
Hemispherx Biopharma, Inc. - Pipeline By Target, H2 2011
Hemispherx Biopharma, Inc. – Pipeline By Route of Administration, H2 2011
Hemispherx Biopharma, Inc. – Pipeline By Molecule Type, H2 2011
Skip to top